Biotech | November 05, 2021
Novavax files emergency use listing with WHO for Covid-19 vaccine
All modules required for regulatory review of Novavax vaccine, including CMC data, are now complete for WHO
All modules required for regulatory review of Novavax vaccine, including CMC data, are now complete for WHO
The preregistrations are aimed at registering both healthy children and those with comorbidities whereas preference will be given for children with comorbidities
The vaccine can be stored at 2 to 8 degrees celsius and traditional cold chain capabilities will suffice
Following the review of around 20 candidate vaccines by the external advisory group, MVC's vaccine was selected as one of two to be included in the global trial
Filing marks first protein-based vaccine submitted to MHRA for authorization
Support from DFC will help produce one billion vaccine doses by the end of 2022
The list of kids with co-morbidities eligible for vaccination would be announced by the government
The interim analysis showed that the MVC-COV1901 vaccine has a good safety profile and elicits promising neutralising antibody titres
The first study to investigate the safety and immunogenicity of both vaccines when co-administered compared to each vaccine administered separately in adults aged 65 years and older
It recommends using the vaccine to prevent the spread of the disease
Subscribe To Our Newsletter & Stay Updated
